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Abstract: Hematological malignancies in humans typically involve two types of genetic 
changes: those that promote hematopoietic cell proliferation and survival (often the result 
of activation of tyrosine kinases) and those that impair hematopoietic cell differentiation 
(often the result of changes in transcription factors). The multi-stage erythroleukemia 
induced in mice by Friend spleen focus-forming virus (SFFV) is an excellent animal model 
for studying the molecular basis for both of these changes. Significant progress has been 
made in understanding the molecular basis for the multi-stage erythroleukemia induced by 
Friend SFFV. In the first stage of leukemia, the envelope protein encoded by SFFV 
interacts with and activates the erythropoietin (Epo) receptor and the receptor tyrosine 
kinase sf-Stk in erythroid cells, causing their Epo-independent proliferation, differentiation 
and survival. In the second stage, SFFV integration into the Sfpi1 locus activates the 
myeloid transcription factor PU.1, blocking erythroid cell differentiation, and in 
conjunction with the loss of p53 tumor suppressor activity, results in the outgrowth of 
malignant cells. In this review, we discuss the current level of understanding of how SFFV 
alters the growth and differentiation of erythroid cells and results in the development of 
erythroleukemia. Our knowledge of how SFFV causes erythroleukemia in mice may give 
us clues as to how the highly related human retrovirus XMRV causes malignancies   
in humans.  
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1. Introduction  
Fifty-three years ago, Charlotte Friend described an acute erythroleukemia induced in adult Swiss 
mice by a viral preparation that subsequently became known as Friend virus [1]. It was later shown 
that this virus preparation contained two retroviruses: (1) a defective spleen focus-forming virus 
(SFFV), which is responsible for the acute erythroleukemia that occurs in adult mice, and (2) a 
replication competent Friend murine leukemia virus (F-MuLV), which is not pathogenic by itself in 
adult mice, but serves as a helper to allow the defective SFFV to infect and integrate into cells. SFFV 
was derived from recombination of Friend MuLV with endogenous polytropic envelope gene 
sequences in the mouse, generating in the process a retrovirus that contains deletions in all of its 
structural genes and a unique envelope gene [2,3].  
SFFV, unlike most acutely transforming retroviruses, does not carry an oncogene but derives its 
oncogenic potential from the product of its unique envelope gene, gp55 [2,3]. Although the SFFV 
envelope gene is closely related to that of the polytropic Friend mink cell focus-inducing MuLV, it 
contains several changes that are responsible for its unique biological effects (Figure 1) [4–6]. First of 
all, it contains a large deletion in the open reading frame of the gene that eliminates a proteolytic 
cleavage site where the envelope protein precursor of a typical MuLV is cleaved into surface unit (SU) 
and transmembrane (TM) proteins. Thus, SFFV gp55 is a fusion protein containing the N-terminal 
domain of SU and the C-terminal domain of TM. Secondly, a single base pair insertion in the 
TM-encoding region of the SFFV env gene results in a change in reading frame. This causes the loss of 
the cytoplasmic tail that is present in a typical MuLV envelope protein and creates a unique 
C-terminus of 5–6 amino acids. Each of these changes in the SFFV env gene are required for 
pathogenicity [7–10]. Unlike a typical MuLV envelope protein, SFFV gp55 does not function as a 
structural protein in the virion. It is inefficiently transported to the plasma membrane, with only   
about 5% of the protein leaving the endoplasmic reticulum as a disulfide-bonded dimer, that is further 
processed through the Golgi to a dimer of 65 kD subunits, which appears on the cell surface [11–14]. 
The cell surface form of the SFFV envelope protein appears to mediate the biological effects of the 
virus [15–17].  
2. Biological Effects of SFFV 
The biological effects of SFFV are specific for the erythroid lineage and can be divided into two 
distinct stages (Figure 2). The first is a preleukemic stage that is the direct result of expression of the 
SFFV envelope protein (Env) in erythroid precursor cells. This causes their uncontrolled proliferation 
leading to rapid erythroid hyperplasia characterized by grossly enlarged spleens and livers. With some 
strains of SFFV, erythropoietin (Epo)-independent differentiation of erythroid cells also occurs, 
resulting in polycythemia. Death, which occurs within three weeks after virus infection, is thought to 
be the result of splenic rupture. The second stage of SFFV-induced disease represents the Viruses 2010, 2                  
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transformation phase and can be detected only late after virus infection or after serial passage of the 
leukemic splenocytes through syngeneic mice. These SFFV-transformed erythroid cells form 
macroscropic colonies in methylcellulose [18] and can be grown as immortal erythroleukemia cell 
lines in culture. Since SFFV is a replication defective virus, studies have routinely been carried out in 
the presence of helper virus. However, the helper virus does not contribute directly to either the 
erythroid hyperplasia or the transformation of erythroid cells induced by the virus complex, since both 
effects can be reproduced using a helper-free preparation of SFFV [19–22].  
Figure 1. Comparison of the SFFV envelope protein with that of a polytropic MuLV. The 
unique envelope glycoprotein encoded by SFFV is the sole determinant of its 
pathogenicity. The envelope precursor of a typical polytropic MuLV is processed to SU 
and TM proteins. In contrast, the SFFV envelope glycoprotein (Env), due to a large 
deletion that eliminates the cleavage site between SU and TM, as well as a single base pair 
insertion in TM, contains fused SU and TM sequences, has a unique transmembrane region 
and lacks a cytoplasmic tail.  
Polytropic
Ecotropic
Unique to SFFV
Polytropic MuLV
Env
Friend SFFV
Env
Cleavage
Site
Proline
Rich
Deleted 
In SFFV
Extracellular
Intracellular
Membrane
Proline
Rich
SU
TM
SU
TM
SU
SU
Polytropic Polytropic
Ecotropic Ecotropic
Unique to SFFV
Polytropic MuLV
Env
Friend SFFV
Env
Cleavage
Site
Proline
Rich
Deleted 
In SFFV
Extracellular
Intracellular
Membrane
Proline
Rich
SU
TM
SU
TM
SU
SU
 
 
2.1. Induction of Erythroid Hyperplasia by SFFV 
The hallmark of the first stage of SFFV-induced leukemia is the induction of Epo-independence. 
While normal erythroid cells require Epo for their proliferation and differentiation, those infected with 
SFFV can proliferate and, depending upon the strain of SFFV, differentiate in the absence of Epo. This 
can be demonstrated in vitro by infecting primary erythroid progenitors with SFFV, which form 
colonies in the absence of Epo (Figure 3). Erythroid cells infected in vitro with SFFV-P, a strain of the 
virus which causes erythroblastosis as well as polycythemia in mice, can both proliferate and 
differentiate in the absence of Epo [23,24], as indicated by the induction of Epo-independent 
hemoglobinized colonies. In contrast, erythroid cells infected in vitro with SFFV-A, a strain that Viruses 2010, 2                  
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causes erythroblastosis without polycythemia in mice, can proliferate in the absence of Epo but still 
require Epo for their differentiation. [25,26]. SFFV can also render Epo-dependent hematopoietic cell 
lines factor-independent [27–29]. The Epo-dependent erythroleukemia cell line HCD-57 can grow in 
the absence of Epo after infection with either SFFV-P or SFFV-A [29], but only SFFV-P can confer 
factor-independence to BaF3-EpoR cells, an IL-3 dependent hematopoietic cell line that has been 
engineered to express the Epo receptor (EpoR) [27,28,30]. The different biological phenotypes 
conferred by SFFV-P and SFFV-A have been attributed to a 113 bp region encompassing the 
membrane spanning domain of the viral envelope protein [31]. This transmembrane region contains 
several amino acid differences between the two viruses, including methionine at position 390 and two 
extra leucine residues in the envelope protein of SFFV-P [32], both of which are required for the 
development of polycythemia in mice and to render BaF3-EpoR cells Epo-independent [33,34].  
Figure 2. SFFV induces a multistage erythroleukemia in mice. Stage 1 is the preleukemic 
stage and is characterized by erythroid hyperplasia and in some cases polycythemia.   
Stage 2, which can best be detected after serial transplantation of Stage 1 cells through 
syngeneic mice, represents the leukemic stage of the disease. SFFV-infected erythroid cells 
from Stage 2 can be established in vitro as transformed cell lines.  
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Not all strains of mice are susceptible to erythroleukemia induction by SFFV. Some strains of mice 
carry genes that prevent the helper virus from infecting or integrating into the target cell, while others 
express genes that lead to the development of an effective immune response against the virus or 
virus-infected cells [35]. In addition, certain resistant strains of mice have genetic defects that alter the 
number of erythroid target cells for the virus. The only host gene that controls the susceptibility of 
erythroid target cells to SFFV is the Fv2 gene [36]. The Fv2 gene encodes the receptor tyrosine kinase 
Stk, and mice must encode a unique form of this kinase to be susceptible to SFFV-induced 
erythroleukemia (see Section 3.3.) [37]. Viruses 2010, 2                  
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2.2. Transformation of Erythroid Cells by SFFV 
The majority of the SFFV-infected erythroid cells proliferating in the first stage of SFFV-induced 
disease have a finite self-renewal capacity. However, SFFV is capable of transforming erythroid cells, 
although the transformed cells are detectable only in the late stages of disease. Since most SFFV 
infected mice die before these transformed cells gain a growth advantage, the virus infected spleen 
cells proliferating during the erythroblastosis phase of the disease are typically serially transplanted to 
syngeneic mice to enrich for the transformed cells (see Figure 1). Unlike erythroid cells present in the 
early stages of SFFV-induced disease, SFFV-transformed cells, called murine erythroleukemia (MEL) 
cells, are monoclonal and are thought to represent the progeny of a single cell that has undergone 
secondary genetic events. MEL cells are capable of growing as subcutaneous tumors in mice and as 
immortal erythroleukemia cell lines in vitro [38–40]. SFFV-transformed MEL cells, unlike those 
proliferating in the first stage of SFFV-induced disease, are blocked in differentiation, although they 
can be induced to differentiate into red blood cells with certain chemicals, but not with Epo [41].  
Figure 3. Epo-independent erythroid proliferation and differentiation induced by SFFV. 
Normal erythroid cells require Epo for proliferation and differentiation into red blood cells 
(RBC). However, erythroid cells infected with SFFV-P or SFFV-A in vitro can proliferate 
in the absence of Epo, as shown by the development of Epo-independent erythroid 
colonies. Those infected with SFFV-P, but not SFFV-A, are red, indicating that 
differentiation also proceeds in the absence of Epo.  
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The mechanisms by which SFFV and its unique envelope protein cause multi-stage 
erythroleukemia in adult mice have been the subject of numerous investigations. Below, we will 
discuss our current level of understanding of how expression of SFFV in erythroid cells leads to 
deregulation of signal transduction pathways to cause erythroid cell hyperplasia, polycythemia and 
transformation.  Viruses 2010, 2                  
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3. Molecular Basis for the Epo-independent Erythroid Hyperplasia induced by SFFV 
Two key characteristics of the first stage of SFFV-induced disease are the higher than normal rate 
of proliferation of erythroid cells and the lack of dependence on Epo for this hyperplasia to occur. 
Studies have shown that Epo-independent proliferation, differentiation and survival of SFFV-infected 
erythroid cells directly results from constitutive activation of signal transduction pathways that is 
mediated by the interaction of the SFFV envelope glycoprotein with two molecules: the EpoR and a 
short form of the receptor tyrosine kinase Stk. 
3.1. Constitutive Activation of Signal Transduction Pathways by SFFV 
Because infection of erythroid cells with SFFV mimics some of the effects of Epo on those cells, 
numerous investigations logically focused on determining whether the unique envelope glycoprotein 
of SFFV, which is the sole determinant of its pathogenicity, was able to activate signaling molecules 
regulated by the interaction of Epo with its dimeric cell surface receptor. Through either 
phosphorylation of the EpoR or of adapter molecules, binding of Epo to the EpoR activates several 
distinct pathways, including the Ras/Raf/MAP kinase, the Jak-Stat, and the PI 3-kinase pathways [42]. 
As was predicted, comparisons of Epo-dependent erythroid cell lines and their SFFV-infected 
counterparts revealed that SFFV activates these same signal transduction pathways. In contrast to 
Epo-stimulated erythroid cells, however, the EpoR is not constitutively phosphorylated in 
SFFV-infected cells [43], indicating that SFFV is activating signals primarily through a redundant 
EpoR pathway involving the activation of adapter molecules, such as members of the IRS family of 
adapters [44,45]. Table 1 summarizes the findings described below regarding activation of signaling 
molecules of the Epo/EpoR pathway by both SFFV-P, which causes Epo-independent proliferation and 
differentiation, and SFFV-A, which causes only Epo-independent proliferation.  
Studies of the Ras/Raf/MAP kinase pathway show that upstream events (including Shc 
phophorylation and Shc-Grb2 complex formation), Ras activation, and activation of downstream 
components (including Raf-1, MEK, and the MAP kinases ERK1/2 and JNK) occur constitutively in 
both SFFV-P and SFFV-A-infected cells [46–48]. While necessary for the proliferation of erythroid 
cells in response to Epo, Raf and Ras are not required for the proliferation of SFFV-infected erythroid 
cells, although proliferation was reduced in the absence of Raf and Ras [46,47]. In contrast, the 
Epo-independent proliferation of SFFV-infected cells absolutely requires activation of ERK and   
JNK [48,49], suggesting that SFFV also activates a Ras/Raf-independent MAP kinase pathway.  
Phosphorylation and translocation to the nucleus of Stats 1, 3 and 5 occurs in SFFV-P-infected 
erythroid cells in the absence of Epo [50,51]; constitutive Stat activation occurs without tyrosine 
phosphorylation of the EpoR and may not require Jak2 activation [43]. In contrast to SFFV-P, SFFV-A 
infection of erythroid cells does not result in the activation of Stats 1 and 5, although Stat3 is 
constitutively activated [52,53]. Thus, activation of Stats 1 and 5 may be necessary for the 
Epo-independent induction of erythroid cell differentiation, which does not occur after infection of 
erythroid cells with SFFV-A. Stat5 increases transcription of the anti-apoptotic protein Bcl-XL in 
erythroid cells in response to Epo [54], and Bcl-XL  may also protect SFFV-infected cells from 
apoptosis after Epo withdrawal. Unlike normal erythroid cells, SFFV-P-infected erythroid cells 
express high levels of this anti-apoptotic protein even after Epo withdrawal [55]. Viruses 2010, 2                  
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Table 1. Signaling components of the Epo/EpoR pathway activated by SFFV. SFFV-P and 
SFFV-A, which have different effects on erythroid cell differentiation, are compared.  
Signaling Components 
of Epo/EpoR Pathway 
 
SFFV-P 
 
SFFV-A 
 
Reference 
Shc  ++ [47] 
Grb2  ++ [47] 
Ras  ++ [47] 
Raf-1  ++ [46] 
MEK  ++ [46] 
ERK 1/2  ++ [46] 
JNK  ++ [48] 
Stat1  + − [50–52] 
Stat3  ++ [50–52] 
Stat5  + − [50–52] 
PI 3-kinase  ++ [43] 
IRS-2  ++ [43] 
Gab1  ++ [43] 
Gab2  ++ [43] 
PKC  ++ [47] 
Akt  ++ [43] 
SHIP  ++ [43] 
 
Both SFFV-P and SFFV-A also activate the PI 3-kinase pathway. Constitutive PI 3-kinase 
activation in SFFV-infected cells results not from its association with the EpoR, which is not tyrosine 
phosphorylated in SFFV-infected cells, but from the association of its p85 regulatory subunit with the 
constitutively phosphorylated adaptor molecules IRS-2, Gab1 and Gab2 [43]. PI 3-kinase activity is 
required for SFFV-induced erythroid cell proliferation: pharmacological inhibition of PI 3-kinase 
activity blocks the Epo-independent proliferation of SFFV-infected cells [43,49], and SFFV-induced 
splenomegaly is attenuated in p85-deficient mice [56]. The serine/threonine protein kinases Akt and 
PKC, downstream effectors of PI 3-kinase, are constitutively phosphorylated in SFFV-infected   
cells [43,47]. MEK is one of the targets activated downstream of PKC; thus, PKC activation could 
explain the Ras/Raf-independent activation of ERK in SFFV-infected cells. In contrast to Ras and Raf, 
PKC is absolutely required for SFFV-induced ERK activation and cell proliferation in the absence of 
Epo [47]. Activation of both PKC and Akt may promote survival of SFFV-infected erythroid cells in 
the absence of Epo. In other systems, PKC has been shown to increase levels of the anti-apoptotic 
protein Bcl-XL [57], and Akt phosphorylates BAD [58], thereby inactivating this pro-apoptotic Bcl-2 
family member.  
Thus, analogous to the effects of Epo on erythroid cells, SFFV activates multiple signal 
transduction pathways that stimulate their growth and differentiation. Activation of MAP kinases,  
PI 3-kinase, PKC and Stat3 are required for Epo-independent proliferation. In contrast, Stats 1 and 5 
appear to be involved in the induction of SFFV-induced Epo-independent differentiation. Protection of 
SFFV-infected erythroblasts against apoptosis may be conferred through the activation of Stat5, PKC 
and Akt. By activating all of these signals, SFFV-P-infected erythroblasts circumvent the normal Viruses 2010, 2                  
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regulation of proliferation, differentiation, and survival, leading to the observed rapid erythroblastosis 
and polycythemia in affected animals.  
3.2. Interaction of SFFV Env With the EpoR  
SFFV Env has no homology to Epo or its receptor, no intrinsic kinase activity, no DNA-binding 
motif, and lacks a cytoplasmic tail to dock signal transducing molecules. Thus, the leading hypothesis 
for its mode of action on erythroid cells was that it interacted with a component(s) of the Epo signal 
transduction pathway at the cell surface that would mediate proliferation and differentiation in the 
absence of Epo. The main candidate for such an interaction was the EpoR. Strong support for this 
hypothesis came from studies demonstrating that the IL-3-dependent cell line BaF3 could be converted 
to factor-independence by SFFV-P infection if and only if a construct driving exogenous expression of 
the EpoR was introduced [28]. Cross-linking studies with iodinated Epo revealed that SFFV Env was 
in close proximity to the EpoR at the cell surface [15,59], establishing that the viral envelope protein is 
in a position where it could alter Epo signal transduction pathways. Co-immunoprecipitation 
experiments demonstrated that an extracytoplasmic region of the EpoR specifically interacts with 
SFFV Env, and studies using chimeric receptors showed that the transmembrane region of the EpoR is 
critical for activation by SFFV Env and for subsequent biological events to occur [60]. Further studies 
showed that serine 238 in the transmembrane region of the EpoR interacts with methionine 390 in the 
envelope glycoprotein of SFFV-P, and it is thought that these specific transmembrane interactions 
induce receptor oligomerization and a conformational change in the EpoR like that induced by   
Epo [33,61]. Although the murine and human EpoRs are closely related, the envelope protein of 
SFFV-P fails to activate the human EpoR, which contains leucine instead of serine at   
position 238 [33]. Unlike SFFV-P, the envelope glycoprotein of SFFV-A cannot interact with and 
activate the EpoR, and this is attributed to the presence of isoleucine at position 390 in SFFV-A  
Env [33].  
Although the envelope glycoprotein of SFFV-P can interact with and activate the EpoR, this 
interaction does not appear to be necessary for the development of Epo-independent erythroid cell 
hyperplasia. SFFV-A, which encodes an envelope protein that cannot activate the EpoR, still   
causes Epo-independent erythroid cell hyperplasia in mice, although the animals do not develop 
polycythemia [25,26]. Furthermore, mice in which the mouse EpoR has been replaced with the human 
EpoR, which cannot be activated by SFFV Env [33], still develop SFFV-P-induced erythroblastosis 
but not polycythemia [52]. Thus, interaction of SFFV-P Env with the EpoR appears to be responsible 
for the development of Epo-independent erythroid differentiation and polycythemia and not required 
for the development of SFFV-induced erythroid cell hyperplasia.  
3.3. Interaction of SFFV Env with the Receptor Tyrosine Kinase sf-Stk 
Since the envelope protein of SFFV lacks any kinase activity, the Epo-independent tyrosine 
phosphorylation of various signal transduction molecules in SFFV-infected cells must involve 
activation of a cellular tyrosine kinase. Although the tyrosine kinase Jak2 plays an important role in 
tyrosine phosphorylation of the EpoR in response to Epo in normal erythroid cells [62], 
Epo-independent EpoR phosphorylation is not observed in SFFV-infected cells, and it is unclear Viruses 2010, 2                  
 
 
2243
whether Jak2 is constitutively activated in these cells [43,52]. Thus, some other kinase must be 
responsible for the multiple signal transducing molecules that are tyrosine phosphorylated in 
SFFV-infected erythroid cells in the absence of Epo. Constitutive activation of several other tyrosine 
kinases that are known to be activated by Epo, including Fes and Tec, was not detected in 
SFFV-infected cells [43]. Although the tyrosine kinase Lyn was shown to be constitutively activated in 
SFFV-infected erythroid cells, it was not required for the induction of Epo-independent erythroid 
colonies by SFFV or for the development of SFFV-induced erythroleukemia [63].  
Eliminating a role for kinases known to be activated by Epo pointed to the possibility that some 
kinase typically not associated with the Epo/EpoR pathway might be involved. This indeed turned out 
to be the case; the responsible kinase is a short form Stk (sf-Stk). The identification of the kinase was 
the outcome of studies to understand the host gene Fv2, which confers susceptibility to SFFV-induced 
erythroleukemia at the level of the erythroid target cell. The Fv2 gene was shown to encode the 
Met-related receptor tyrosine kinase Stk [37]. Stk is the receptor for macrophage stimulating protein, 
which regulates macrophage motility [64]. The Stk gene, Mst1r, is expressed as a full length message, 
encompassing all 19 exons of the gene [65], and, in some cases, also as a shorter message transcribed 
from an internal promoter in intron 10 of Mst1r. The short message only contains exons 11–19, thus 
the encoded sf-Stk protein contains the transmembrane and tyrosine kinase domains of Stk but lacks 
most of its extracellular domain, including the ligand binding domain (see Figure 4) [66]. Although all 
strains of mice express the full length form of the kinase, only those strains susceptible to 
SFFV-induced erythroleukemia express sf-Stk [37]. Resistant strains of mice fail to express the short 
form due to a 3 bp deletion that includes the 5’-most nucleotide of the short transcript and that disrupts 
a GATA-1 transcription factor binding site in the internal promoter from which this transcript is 
expressed. Wild mice of the genus Mus spretus are also resistant to SFFV-induced disease, and 
although the sequence of their Mst1r gene includes the 3 bp deletion found in resistant laboratory 
strains, it also contains a point mutation in a Myb transcription factor binding site within the intron 10 
promoter [37]. Consistent with the erythroid specificity of SFFV-induced disease, erythroid cells are 
one of the few types of cells that abundantly express sf-Stk [66]. The physiological role of sf-Stk is 
unknown. Exogenous expression of sf-Stk in Fv2 resistant mice is sufficient to make them susceptible 
to SFFV disease [37]. By virtue of its requirement to activate SFFV-induced Epo-independent 
signaling in erythroid cells and erythroleukemia in mice, sf-Stk became a likely candidate to mediate 
the activation of signal transduction pathways by SFFV, and subsequent studies focused on confirming 
this hypothesis.  
Sf-Stk is phosphorylated in leukemic splenocytes from SFFV-infected mice, but not those from 
uninfected mice [67], suggesting that SFFV activates sf-Stk. A direct covalent interaction between 
SFFV Env and sf-Stk was demonstrated when sf-Stk and SFFV Env were co-expressed in the 
BaF3-EpoR cell line [68]. In contrast, a weakly pathogenic mutant of SFFV, BB6, fails to interact with 
and activate sf-Stk. BB6 lacks two of the four cysteines in the ecotropic extracellular domain of 
SFFV-P Env, suggesting that these cysteines in SFFV-P Env may be responsible for disulfide bond 
formation with those present in the extracellular domain of sf-Stk [68]. Recent studies confirm that the 
interaction of SFFV Env and sf-Stk requires disulfide bond formation between at least two of the 
cysteines of the ecotropic domain of SFFV Env and cysteines of the extracellular domain of   
sf-Stk [69]. Interaction of SFFV Env and sf-Stk prolongs the half-life of sf-Stk [67] and results in Viruses 2010, 2                  
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sf-Stk phosphorylation and its association with multiple tyrosine-phosphorylated proteins [43]. SFFV 
Env does not interact with full-length Stk [43], possibly due to steric hindrance. 
The interaction between SFFV Env and sf-Stk is critical for the induction of Epo-independence by 
the virus. Erythroid progenitors from Fv2 resistant (i.e. sf-Stk null) mice, which do not form erythroid 
colonies in vitro in the absence of Epo, are able to form Epo-independent colonies following SFFV 
infection if they are first engineered to express sf-Stk [49], or if they are infected with a bicistronic 
retroviral vector allowing coexpression of SFFV Env and sf-Stk [67]. Sf-Stk alone does not induce 
Epo-independent erythroid colony formation. A constitutively activated mutant of sf-Stk induces   
Epo-independent erythroid colony formation in the absence of SFFV Env [67], further supporting the 
hypothesis that interaction with SFFV Env activates sf-Stk kinase activity. 
Figure 4. Comparison of full length and short form Stk. The Mst1r gene generates a full 
length transcript which encodes Stk, a tyrosine kinase that serves as the cell surface 
receptor for macrophage stimulating protein (MSP). The Mst1r gene also uses an internal 
promoter (Pro2) to encode a short form of Stk (sf-Stk), which lacks the MSP binding 
domain and whose function is unknown. Strains of mice resistant to SFFV-induced 
erythroleukemia do not encode sf-Stk due to a 3 bp deletion in the internal promoter. 
Although sf-Stk lacks a signal sequence, it is shown in the membrane for comparison.  
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Mutational analyses of sf-Stk have revealed domains required for the induction of 
Epo-independence. First and foremost, the tyrosine kinase domain is required; a kinase-dead mutant of 
sf-Stk could not induce Epo-independent colonies in conjunction with SFFV [49,67]. In addition, the 
most C-terminal tyrosine (amino acid 1337), which is one of two tyrosines comprising a 
multifunctional docking site, is essential [49,67]. The binding of the adapter molecule Grb2 to this 
tyrosine is important for the induction of Epo-independent erythroid colonies by SFFV-P [49], and 
haploid insufficiency of Grb2 decreases the susceptibility of mice to SFFV-P [70]. After binding to Viruses 2010, 2                  
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SFFV Env-activated sf-Stk, Grb2 recruits Gab2, another adapter found to be tyrosine phosphorylated 
in SFFV-infected cells [70]. Phosphorylated Gab2 can recruit SHP-2 and the p85 regulatory subunit of 
PI 3-kinase, molecules important for the SFFV-induced activation of the Ras/MAP kinase and   
PI 3-kinase pathways, respectively. This is supported by recent data indicating that PI 3-kinase p85α 
can be co-immunoprecipitated with sf-Stk. This co-immunoprecipitation requires sf-Stk kinase activity 
and tyrosine 436 in the multifunctional docking site of the kinase, suggesting that the interaction 
occurs indirectly via phosphorylated adaptor proteins such as Gab2 [56]. A recent study described a 
novel binding site by which Gab2 can also recruit Stat3 [71]. Interestingly, sf-Stk kinase activity is not 
required for the phosphorylation of Gab2 or Stat3 following their recruitment to the receptor [71]; 
these observations suggest that sf-Stk may be acting as a scaffold for these adapters rather than causing 
their phosphorylation. Although Gab2 null mice still develop erythroleukemia after infection with 
SFFV-P, progression of the disease is much slower, with significantly less splenomegaly observed at 
two weeks after infection [70], similar to that observed in SFFV-P-infected mice deficient in the p85α 
subunit of PI 3-kinase [56]. Thus, Grb2, Gab2 and Stat3 are all important mediators of signals coming 
from SFFV Env-activated sf-Stk, which seems to serve dual roles as both kinase and scaffold. 
It is of interest to consider when, where, and how SFFV Env and sf-Stk interact within an infected 
cell. SFFV Env forms dimers in the endoplasmic reticulum that migrate through the Golgi to the cell 
surface [11,13]. Thus, each SFFV Env dimer could bind two molecules of sf-Stk. Although this might 
be a mechanism for bringing two molecules of sf-Stk close enough together for transphosphorylation 
to occur, recent data demonstrate that oligomerization of sf-Stk occurs independently of SFFV Env [69]. 
However, phosphorylation of sf-Stk is dependent upon SFFV Env [68,69]. Sf-Stk lacks an N-terminal 
signal sequence, and its interaction with SFFV Env is responsible for redirecting it from the cytosol to 
the cell membrane [69]. SFFV Env could stimulate the phosphorylation of sf-Stk by causing a 
conformational change in sf-Stk, possibly enhancing autophosphorylation, and/or by bringing sf-Stk to 
a region of the cell membrane where it can interact with another kinase. 
Activation of sf-Stk, in contrast to activation of the EpoR, is absolutely required for the 
development of SFFV-induced erythroblastosis, indicating that signals initiated by this virus-activated 
kinase are essential. Not only can SFFV Env activate sf-Stk in erythroid cells, it can activate the kinase 
in rodent fibroblasts that have been engineered to express sf-Stk, and this activation can be measured 
by observing transformation of the fibroblasts. Since fibroblasts do not express the EpoR, these 
sf-Stk-expressing cells have been beneficial in studying signals resulting from SFFV Env-activated 
sf-Stk in the absence of EpoR signaling [72]. The envelope proteins of both SFFV-P and SFFV-A can 
transform sf-Stk-expressing rodent fibroblasts [72], indicating that both of these viral proteins can 
interact with and activate sf-Stk. This result is consistent with the ability of both SFFV-P and SFFV-A to 
cause erythroleukemia in mice. As previously observed in SFFV-infected erythroid cells, interaction of 
SFFV Env and sf-Stk in fibroblasts results in the activation of components of the MAPK and PI 3-kinase 
pathways, and these pathways are required for anchorage-dependent and -independent proliferation of the 
transformed cells [73]. Stat3 is also activated in the transformed rodent fibroblasts [73], consistent with 
studies indicating that Stat3 is activated downstream of sf-Stk in erythroid cells [71]. The p38 MAP 
kinase stress pathway, which is suppressed in SFFV-infected erythroid cells [55], is also suppressed in 
fibroblasts co-expressing SFFV Env and sf-Stk [73]. The only signal transducing molecules activated 
in SFFV-infected erythroid cells that are not activated in fibroblasts co-expressing SFFV Env and  Viruses 2010, 2                  
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sf-Stk are Stats 1 and 5 [73], suggesting that activation of these Stats may require the involvement of 
the EpoR.  
3.4. Different Roles of EpoR Signaling and sf-Stk in SFFV-induced Disease 
It is clear that the envelope protein of SFFV can interact not only with the EpoR but also with the 
tyrosine kinase sf-Stk, and these interactions cause constitutive activation of signal transduction 
pathways in SFFV-infected cells, as illustrated in Figure 5. In this figure, interaction of SFFV Env 
with the EpoR and sf-Stk are shown separately to illustrate the distinct signals generated, but it is 
likely that all three interact in erythroid cells, although the exact stoichiometry of the interactions is 
unknown. Most of the signals generated from the interaction of SFFV Env with either the EpoR or 
sf-Stk are common, and signals from both interactions may be required to raise the level of these 
common signals above a certain threshold to cause a biological effect. However, there are also some 
differences in the signals generated from the interaction of SFFV Env with either the EpoR or sf-Stk, 
and these may be responsible for the induction of Epo-independent proliferation versus differentiation 
by SFFV.  
Figure 5. The envelope protein of SFFV interacts with the EpoR and sf-Stk to activate 
signal transduction pathways for growth, differentiation and survival of erythroid cells. 
(A) SFFV Env interacts with the EpoR, causing phosphorylation of the adaptor molecules 
IRS-2 and Gab1/2. This leads to activation of the Ras/Raf/MAPK and PI3-K pathways and 
phosphorylation of Stats 1 and 5, resulting in Epo-independent proliferation, differentiation 
and survival. (B) Covalent interaction of SFFV Env with sf-Stk results in activation of 
Grb2, Gab2 and Stat3. This leads to activation of the Ras/Raf/MAPK and   
PI-3K pathways and Epo-independent erythroid cell proliferation and survival.   
P = phosphorylation event; S-S = disulfide bond. 
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The interaction of SFFV Env with the EpoR appears to be required for the development of 
Epo-independent erythroid cell differentiation, not proliferation. Two signal transducing molecules 
activated by the interaction of SFFV Env with the EpoR, but not with sf-Stk, are Stat1 and Stat5 
(Figure 5A). These transcription factors play a role in erythroid cell differentiation, and their activation 
in SFFV-P-infected, but not SFFV-A-infected, erythroid cells is likely to be responsible for the 
polycythemia uniquely induced by SFFV-P. The observation that SFFV-P can cause erythroblastosis 
but not polycythemia in Stat5 null mice [52] further supports a role for Stat5 in SFFV-P-mediated 
erythroid cell differentiation, but not proliferation. In contrast to the interaction of SFFV Env with the 
EpoR, its interaction with sf-Stk appears to be the major force driving the Epo-independent 
proliferation of erythroid cells. One of the signals that is activated by this interaction, and not 
interaction of SFFV Env with the EpoR, is the transcription factor Stat3 (Figure 5B). In contrast to 
Stats 1 and 5, Stat3 appears to be important for Epo-independent proliferation induced by SFFV. In 
addition, activation of Stat3, but not Stats 1 and 5, occurs in transformed fibroblasts co-expressing 
SFFV Env and sf-Stk, further indicating that Stat3 plays an important role downstream of sf-Stk in 
inducing cellular proliferation. Blocking Stat3 activity interferes with the ability of SFFV-P to induce 
splenomegaly in mice and Epo-independent erythroid colonies in vitro, demonstrating that Stat3 is 
required for the induction of Epo independence by SFFV [71,74]. Interestingly, Stat3 has been shown 
in a number of systems to be an oncogene, and it is constitutively activated in various human 
hematological malignancies [75]. One role for Stat3 during the first stage of SFFV-P-induced 
erythroleukemia may be to limit the differentiation of erythroid precursors through the induction of the 
myeloid transcription factor PU.1 [74], expanding the number of erythroid target cells for the virus. 
Erythroid hyperplasia induced by SFFV-A does not depend on Stat3-mediated PU.1 induction since 
this virus does not promote Epo-independent differentiation.  
As mentioned previously, the biological effects of SFFV in mice are specific to the erythroid 
lineage, which are the only hematopoietic cells that express the EpoR. However, interaction of SFFV 
Env and the EpoR are not sufficient or essential for the development of Epo-independent erythroid 
hyperplasia by SFFV. Thus, the role that the EpoR plays in SFFV-induced erythroid hyperplasia is 
unclear. Perhaps its function is not to signal but to bring sf-Stk, by virtue of its interaction with SFFV 
Env, to a cellular compartment where it can interact with and activate signal transducing molecules. 
The erythroid specificity of SFFV-induced disease could also be the consequence of erythroid cells, 
being one of the few cells in mice that express sufficient levels of sf-Stk to be activated by SFFV Env. 
Lending support to this idea is the observation that a bicistronic vector co-expressing sf-Stk and SFFV Env 
causes non-erythroid diseases in mice, such as hemangiosarcomas and ovarian and uterine   
tumors [67]. Finally, SFFV may be activating other signal transduction pathways unique to erythroid cells 
that do not involve the EpoR. A recent study suggested that the rapid expansion of erythroid progenitors in 
the spleens of SFFV-infected mice required activation of the BMP-4-dependent stress erythropoiesis 
pathway [76]. This pathway does not appear to depend upon the EpoR but may involve sf-Stk.  
4. Molecular Basis for the Transformation of Erythroid Cells by SFFV  
While interaction of the SFFV envelope protein with the EpoR and sf-Stk can account for the early 
polyclonal, Epo-independent proliferation of SFFV-infected erythroid cells, such interactions are not Viruses 2010, 2                  
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sufficient to induce a truly malignant disease. Additional molecular events are required. SFFV, like 
other retroviruses, is thought to transform erythroid cells by insertional mutagenesis. When malignant 
cells from SFFV-infected mice are examined for common sites of integration, almost all of them 
contain SFFV integrated at the Sfpi1 locus [77–79]. This results in non-physiological levels of the 
myeloid transcription factor PU.1 in erythroid cells, which is thought to abrogate the commitment of 
these cells to differentiate, leading to their transformation (Figure 6) [80]. 
Figure 6. Transformation of erythroid cells by SFFV. SFFV integrates near the Sfpi1 gene, 
resulting in the expression of non-physiological levels of the transcription factor PU.1 in 
erythroid cells. PU.1 causes the upregulation of the tyrosine phosphatase SHP-1, which 
dephosphorylates Stat1. It is unknown whether PU.1 regulation of SHP-1 levels is direct or 
indirect. Phosphorylated Stat1, which is transported to the nucleus where it binds DNA, is 
thought to play a role in erythroid cell differentiation. Unphosphorylated Stat1 in 
SFFV-transformed cells cannot bind DNA, leading to a block in erythroid cell 
differentiation. Combined with the inactivation of the tumor suppressor gene p53, this 
leads to the outgrowth of transformed erythroid cells. 
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Because SFFV does not block erythroid cell differentiation in the first stage of the disease, and 
some strains of the virus can even promote Epo-independent differentiation, it seemed likely that the 
genetic events associated with SFFV-induced transformation involved specifically blocking signals 
associated with erythroid cell differentiation. Stat transcription factors, particularly Stats 1 and 5, are 
thought to play a role in Epo-induced erythroid cell differentiation [52,81]. In the first stage of 
SFFV-P-induced disease, both Stats 1 and 5 are constitutively phosphorylated and bind DNA [52,82]. 
In contrast, Stat1 DNA binding is blocked in SFFV-transformed cells from the second stage of the Viruses 2010, 2                  
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disease, even in the presence of Epo [82]. Interferon-α is able to induce Stat1 activity in these 
SFFV-transformed cells, indicating that the block is specific to Stat activation by Epo or SFFV and not 
at the level of Stat1 expression. Also, the block is specific to activation of Stat1, not other signal 
transducing molecules activated in Stage 1, since both MAPK and Akt kinase are still constitutively 
activated in SFFV-transformed erythroid cells. There is a direct correlation in SFFV-infected erythroid 
cells between expression of PU.1 and inhibition of Stat1 DNA-binding activity [82], suggesting that 
PU.1 expression in erythroid cells may be causing the block in Stat1 activation.  
Stat proteins are phosphorylated in the cytoplasm, form dimers and then are transported to the 
nucleus where they bind DNA. The block in Stat1 DNA binding in SFFV transformed cells is at the 
level of Stat1 tyrosine phosphorylation [82], implying a change in an enzyme that regulates 
phosphorylation status. Activation of Jak2, the major regulator of Stat tyrosine phosphorylation in 
erythroid cells, was not blocked in SFFV-transformed erythroid cells. Rather SFFV-transformed 
erythroid cells were shown to express high levels of the hematopoietic phosphatase SHP-1, which has 
previously been shown to negatively regulate the Jak-Stat pathway  [83]. When SFFV-transformed 
cells were treated with the phosphatase inhibitor orthovanadate, both Epo-induced and constitutive 
Stat1 phosphorylation were restored, indicating that SHP-1 or another phosphatase is responsible for 
the block in Stat1 phosphorylation [82]. Interestingly, SHP-1 is downregulated in erythroid cells from 
PU.1 deficient mice [84], suggesting that PU.1 may directly or indirectly regulate SHP-1 expression. 
Furthermore, when SFFV-transformed cells are treated with chemicals to induce their differentiation, 
not only do the levels of PU.1 go down, but SHP-1 levels decrease and Stat1 DNA binding activity is 
restored [82].  
While activation of PU.1 is an early and critical event in the transformation of erythroid cells by 
SFFV, another genetic event also occurs which is thought to enhance the outgrowth of 
SFFV-transformed cells: the loss of activity of the tumor suppressor p53 [85–88]. The loss of p53 activity 
is due either to SFFV integration, which blocks expression of the gene, or to spontaneous point mutations 
or deletions, resulting in an inactive protein. The outgrowth of SFFV-transformed erythroid cells occurs 
more rapidly in p53 null mice or mice expressing a dominant-negative mutant p53 transgene [86,89].  
Thus, as illustrated in Figure 6, integration of the SFFV genome into the Sfpi1 locus in erythroid 
cells leads to transformation of erythroid cells by activating the myeloid transcription factor PU.1. 
Expression of inappropriately high levels of PU.1 in SFFV-infected erythroid cells results in an 
increase in the level of SHP-1, favoring dephosphorylation of Stat1 over its phosphorylation and 
blocking its DNA binding activity. Decreased levels of Stat1 DNA binding, cause a block in erythroid 
cell differentiation, favoring proliferation over differentiation. These events, combined with the 
inactivation of the p53 tumor suppressor gene, are thought to favor the outgrowth of truly malignant, 
SFFV-infected erythroid cells. 
5. Conclusions 
We can conclude, from studies to understand the molecular events occurring in SFFV-infected 
erythroid cells, that the virus causes a multi-stage erythroleukemia in mice by deregulating signal 
transduction pathways required for erythroid cell growth, differentiation, and survival (see Figure 7). 
The Epo-independent erythroid cell hyperplasia that occurs within weeks of virus infection is Viruses 2010, 2                  
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accomplished by interaction of the unique envelope glycoprotein of SFFV with the tyrosine kinase 
sf-Stk, leading to constitutive activation of various signal transduction pathways. SFFV Env can also 
interact with the EpoR, but this interaction drives Epo-independent differentiation, causing 
polycythemia, and does not appear to be essential for the development of erythroid hyperplasia. In 
fact, signals generated downstream from SFFV Env-activated sf-Stk can limit this differentiation, 
allowing for the rapid outgrowth of Epo-independent erythroid cells in the first stage of the disease. In 
the second stage, secondary genetic events caused by SFFV integration into host DNA cause a 
complete block in erythroid cell differentiation, even in the presence of Epo. This is the result of 
activation of the myeloid transcription factor PU.1, whose expression in erythroid cells interferes with 
signals required for erythroid cell differentiation, resulting in the outgrowth of fully transformed 
erythroid cells.  
Figure 7. Molecular basis for the multi-stage erythroleukemia induced by SFFV. In 
Stage 1, expression of SFFV Env in erythroid cells results in the activation of sf-Stk and 
Epo signal transduction pathways, rapidly leading to a polyclonal expansion of 
Epo-independent erythroid cells and the development of polycythemia. Stage 2 occurs 
when an erythroid cell within this proliferating population expresses high levels of the 
transcription factor PU.1 due to SFFV integration, causing a block in erythroid cell 
differentiation. Serial passage of SFFV-infected splenic erythroblasts from Stage 1 through 
syngeneic mice allows the outgrowth of these rare SFFV-transformed cells, which are 
monoclonal and can be grown as erythroleukemia cell lines in vitro.  
 
 
Recent studies have demonstrated an association of a recently identified human retrovirus with 
prostate cancer [90,91] and chronic fatigue syndrome [92]. This virus, xenotropic murine leukemia 
virus-related virus (XMRV), is closely related to SFFV and other murine leukemia viruses [91,93]. 
Although it is not known whether XMRV infection is the direct cause of these diseases, its similarity 
to SFFV and to other murine leukemia viruses that can cause malignant and neurological diseases in 
rodents suggests that it could use similar mechanisms to cause disease in humans. Because of its close 
relationship to the envelope protein of SFFV, it is possible that the XMRV envelope protein could also Viruses 2010, 2                  
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interact with a host tyrosine kinase to activate signal transduction pathways leading to cellular 
hyperplasia and transformation. Also, like SFFV, XMRV can integrate into the host genome [94], 
potentially activating oncogenes and leading to cellular transformation. Critical questions regarding 
the relationship of XMRV to human disease are being addressed in a number of laboratories; the 
knowledge of the molecular events that are responsible for the various stages of SFFV-induced 
erythroleukemia should be invaluable in designing in vitro and in vivo studies to determine the 
pathological potential of XMRV.  
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